Recce Pharmaceuticals

Recce Pharmaceuticals Rule of 40

The Rule of 40 of Recce Pharmaceuticals (RCE.AX) as of Nov 22, 2026 is -255.38 %. In the previous year, Rule of 40 was -423.35 % — a change of -39.68% (higher).

Rule of 40

-255.38 %

YoY

-39.68%

Last updated:

Rule of 40 of Recce Pharmaceuticals is 2025 -255.38 % . Rule of 40 of Recce Pharmaceuticals was 2024 -423.35 % . It decreases by -39.68% higher compared to the previous year.

The Recce Pharmaceuticals Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
598.37 AUD
Jan 1, 2019
-550.35 AUD
Jan 1, 2020
-417.05 AUD
Jan 1, 2021
-892.39 AUD
Jan 1, 2022
-370.28 AUD
Jan 1, 2023
-355.40 AUD
Jan 1, 2024
-423.35 AUD
Jan 1, 2025
-255.38 AUD
The Recce Pharmaceuticals Rule of 40 history
YEARRule of 40YoY
-255.38 %-39.68%
-423.35 %+19.12%
-355.40 %-4.02%
-370.28 %-58.51%
-892.39 %+113.98%
-417.05 %-24.22%
-550.35 %-191.97%
598.37 %-125.93%
-2,307.54 %-13.51%
-2,668.12 %+605.92%
-377.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recce Pharmaceuticals stock

Rule of 40 of Recce Pharmaceuticals is -255.38 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Recce Pharmaceuticals

All Key Metrics — Recce Pharmaceuticals